Abstract
Plasma cell dyscrasias are a group of related disorders that have in common the clonal proliferation of plasma cells with resultant production of a monoclonal immunoglobulin that can be detected on serum protein electrophoresis (M-spike). This term incorporates the Plasma Cell Neoplasms along with other related disorders that are not considered malignant. Comprehensive genomic studies have greatly advanced our understanding of the genetic complexity of these diseases in recent years, however they continue to be considered incurable with a highly heterogeneous phenotype. It is clear that a deeper level of knowledge of the biological events underlying the development of these diseases is needed to identify new targets and generate effective novel therapies. MicroRNAs (miRNAs), which are single strand, 20- nucleotide, non-coding RNAs, are key regulators of gene expression and have been reported to exert transcriptional control in multiple myeloma and other plasma cell dyscrasias. miRNAs are now recognized to play a role in many key areas such as cellular proliferation, differentiation, apoptosis and stress response. Substantial advances have been made in recent years in terms of our understanding of the biological role of miRNAs in this complex and diverse set of disorders, leading to the new information, which is of diagnostic and prognostic relevance.
Keywords: MGUS, miRNA, multiple myeloma, plasma cell, regulation, waldenstrom’s macroglobulinemia.
MicroRNA
Title:The Role of miRNAs in Plasma Cell Dyscrasias
Volume: 2 Issue: 3
Author(s): Siobhan Glavey, Salomon Manier, Antonio Sacco, Giuseppe Rossi, Irene M. Ghobrial and Aldo M. Roccaro
Affiliation:
Keywords: MGUS, miRNA, multiple myeloma, plasma cell, regulation, waldenstrom’s macroglobulinemia.
Abstract: Plasma cell dyscrasias are a group of related disorders that have in common the clonal proliferation of plasma cells with resultant production of a monoclonal immunoglobulin that can be detected on serum protein electrophoresis (M-spike). This term incorporates the Plasma Cell Neoplasms along with other related disorders that are not considered malignant. Comprehensive genomic studies have greatly advanced our understanding of the genetic complexity of these diseases in recent years, however they continue to be considered incurable with a highly heterogeneous phenotype. It is clear that a deeper level of knowledge of the biological events underlying the development of these diseases is needed to identify new targets and generate effective novel therapies. MicroRNAs (miRNAs), which are single strand, 20- nucleotide, non-coding RNAs, are key regulators of gene expression and have been reported to exert transcriptional control in multiple myeloma and other plasma cell dyscrasias. miRNAs are now recognized to play a role in many key areas such as cellular proliferation, differentiation, apoptosis and stress response. Substantial advances have been made in recent years in terms of our understanding of the biological role of miRNAs in this complex and diverse set of disorders, leading to the new information, which is of diagnostic and prognostic relevance.
Export Options
About this article
Cite this article as:
Glavey Siobhan, Manier Salomon, Sacco Antonio, Rossi Giuseppe, Ghobrial M. Irene and Roccaro M. Aldo, The Role of miRNAs in Plasma Cell Dyscrasias, MicroRNA 2013; 2 (3) . https://dx.doi.org/10.2174/2211536602666131126002144
DOI https://dx.doi.org/10.2174/2211536602666131126002144 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
Call for Papers in Thematic Issues
Modulatory Roles of Non-coding RNAs in cancer therapy
This thematic issue aims to elucidate the most recent research on ncRNAs in CRCs and discuss the importance and difficulties that may arise in applying this tool on a regular clinical basis.read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Cancer Cells with Photoactive Silica Nanoparticles
Current Pharmaceutical Design Synthesis and Biological Study of Novel Indole-3-Imine-2-on Derivatives as Src Kinase and Glutathione S-Transferase Inhibitors
Letters in Drug Design & Discovery miRNAs as Modulators of Cholesterol in Breast Cancer Stem Cells: An Approach to Overcome Drug Resistance in Cancer
Current Drug Targets Targeting Molecular Imaging of Breast Cancer by Radioimmunodetection Method in Nuclear Medicine
Current Molecular Imaging (Discontinued) Preface
Current Signal Transduction Therapy Methotrexate Induced Pneumonitis: A Review Article
Current Respiratory Medicine Reviews Strategies for Increasing the Solubility and Bioavailability of Anticancer Compounds: β-Lapachone and Other Naphthoquinones
Current Pharmaceutical Design Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients
Current Pharmaceutical Biotechnology HLA Peptide-mediated Strategies for Modulation of Cellular and Humoral Immune Response in Transplantation
Current Pharmacogenomics Recent Progress of Src Family Kinase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry An Update on JAK Inhibitors
Current Medicinal Chemistry Current Strategies for the Treatment of Ulcerative Colitis
Recent Patents on Inflammation & Allergy Drug Discovery State of the Art of Biochemical Markers in Metastatic Bone Disease and the Role of Bisphosphonates as Therapeutic Agents
Current Pharmaceutical Analysis A Review of Preclinical Experiments Toward Targeting M2 Macrophages in Prostate Cancer
Current Drug Targets NF-κB Signaling and Carcinogenesis
Current Pharmaceutical Design Mesenchymal Stromal Cells from Umbilical Cord Blood
Current Stem Cell Research & Therapy Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer
Current Cancer Therapy Reviews Progresses in TCM Metal-Based Antitumour Agents
Anti-Cancer Agents in Medicinal Chemistry Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy
Current Pharmaceutical Design The Changing Face of HDAC Inhibitor Depsipeptide
Current Cancer Drug Targets